<?xml version="1.0" encoding="UTF-8"?>
<html>
   <head/>
   <body>
      <div class="hl7Message">
         <p>MSH|^~\&amp;|NIST Test Lab APP|NIST Lab Facility||NIST EHR Facility|20150926140551||ORU^R01^ORU_R01|LRI_4.2_2.1-NG_FRN|D|2.<br/>5.1|||AL|AL|||||LRI_Common_Component^^2.16.840.1.113883.9.16^ISO~LRI_NG_Component^^2.16.840.1.113883.9.13^ISO~LRI_FRN_Co<br/>mponent^^2.16.840.1.113883.9.84^ISO<br/>
         </p>
         <p>PID|1||PATID1234^^^NIST MPI^MR||Jones^William^A^^^^L||19610627|M||2106-3^White^HL70005||||||||PATID1234^^^NIST MPI^AN<br/>
         </p>
         <p>ORC|RE|ORD723222-4^NIST EHR|R-783274-4^NIST Lab Filler|GORD874255^NIST EHR||||||||5742200012^Radon^Nicholas^^^^^^NPI^L^<br/>^^NPI<br/>
         </p>
         <p>OBR|1|ORD723222-4^NIST EHR|R-783274-4^NIST Lab Filler|625-4^Bacteria identified in Stool by Culture^LN^3456543^CULTURE <br/>STOOL^99USL^2.52^^Stool Culture|||201509231400|||||||||5742200012^Radon^Nicholas^^^^^^NPI^L^^^NPI||||||20150926140551|||<br/>F|||10092000194^Hamlin^Pafford^^^^^^NPI^L^^^NPI|||||||||||||||||||MIC^Observation of type microbiology^HL70411^^^^2.5.1|<br/>|CC^Copies Requested^HL70507<br/>
         </p>
         <p>OBX|1|CWE|625-4^Bacteria identified in Stool by Culture^LN^^^^2.52^^Stool Culture|^1^1^Islt-1|103429008^Enterohemorrhag<br/>ic Escherichia coli, serotype O157:H7^SCT^^^^201509USEd^^Shiga toxin producing E. coli O157:H7 isolated|||A|||F|||201509<br/>231400|||||201509251930||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^B|5432178916^<br/>Knowsalot^Phil^J.^^^^^NPI^L^^^NPI||||RSLT<br/>
         </p>
         <p>NTE|1|| Susceptibility testing for E.coli is not performed, because antibiotics should not be used to treat this infect<br/>ion. There is no evidence that treatment with antibiotics is helpful, and taking antibiotics may increase the risk of he<br/>molytic-uremic syndrome (HUS). Antidiarrheal agents like Imodium may also increase that risk. Non-specific supportive th<br/>erapy, including hydration, is important.<br/>
         </p>
         <p>OBX|2|CWE|625-4^Bacteria identified in Stool by Culture^LN^^^^2.52^^Stool Culture|^2^1^Islt-2|398567006^Salmonella I, g<br/>roup O:4^SCT^^^^201509USEd^^Salmonella I, group O:4 isolated|||A|||F|||201509231400|||||201509251930||||Century Hospital<br/>^^^^^CLIA^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^B|5432178916^Knowsalot^Phil^J.^^^^^NPI^L^^^NPI||||RSLT<br/>
         </p>
         <p>NTE|1||Salmonella gastrointestinal infections usually resolve in 5-7 days and most do not require treatment other than <br/>oral fluids. Persons with severe diarrhea may require rehydration with intravenous fluids. Antibiotic therapy can prolon<br/>g the duration of excretion of non-typhoidal Salmonella and is recommended only for patients with severe illness (e.g., <br/>those with severe diarrhea, high fever, bloodstream infection, or who need hospitalization) or those at risk of severe d<br/>isease or complications, including young infants, older adults (over 65 years old) and immunocompromised persons. Antibi<br/>otic resistance is increasing among some Salmonella bacteria; therefore, susceptibility testing can help guide appropria<br/>te therapy. Choices for antibiotic therapy for severe infections include fluoroquinolones, third-generation cephalospori<br/>ns, and ampicillin (for susceptible infections).<br/>
         </p>
         <p>OBX|3|CWE|625-4^Bacteria identified in Stool by Culture^LN^^^^2.52^^Stool Culture|^3^1^Islt-3|85729005^Shigella flexner<br/>i^SCT^^^^201509USEd^^Shigella flexneri isolated|||A|||F|||201509231400|||||201509251930||||Century Hospital^^^^^CLIA^XX^<br/>^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^B|5432178916^Knowsalot^Phil^J.^^^^^NPI^L^^^NPI||||RSLT<br/>
         </p>
         <p>NTE|1||Antibiotic treatment is recommended for patients with severe disease, bloody diarrhea, or compromised immune sys<br/>tems. Resistance to traditional first-line drugs like ampicillin and trimethoprim-sulfamethoxazole is common, and resist<br/>ance to some other antibiotics is increasing. With this in mind, antibiotic susceptibility testing can help guide approp<br/>riate therapy. When an ampicillin- or trimethroprim-sulfamethoxazole-resistant strain is isolated, choices for therapy i<br/>nclude fluoroquinolones, ceftriaxone, and azithromycin.<br/>
         </p>
         <p>SPM|1|S-2015-66&amp;GoodHealthC_EHR^S-9911-33&amp;NIST Lab Filler||119339001^Stool specimen^SCT^^^^201509USEd^^Stool|||||||||||<br/>||201509231400<br/>
         </p>
         <p>ORC|RE||R-783274-4^NIST Lab Filler|GORD874255^NIST EHR||||||||5742200012^Radon^Nicholas^^^^^^NPI^L^^^NPI|||||||||||||||<br/>||||625-4^Bacteria identified in Stool by Culture^LN^3456543^CULTURE STOOL^99USL^2.52^^Stool Culture<br/>
         </p>
         <p>OBR|2||R-783274-4^NIST Lab Filler|50545-3^Bacterial susceptibility panel in Isolate by Minimum inhibitory concentration<br/> (MIC)^LN^^^^2.52^^Bacteria susceptibility|||201509231400||||G|||||5742200012^Radon^Nicholas^^^^^^NPI^L^^^NPI||||||20150<br/>927112054|||F|625-4&amp;Bacteria identified in Stool by Culture&amp;LN&amp;&amp;&amp;&amp;2.52&amp;&amp;Stool Culture^&amp;2&amp;1&amp;Islt-2||10092000194^Hamlin^Pa<br/>fford^^^^^^NPI^L^^^NPI|ORD723222-4&amp;NIST EHR^R-783274-4&amp;NIST Lab Filler||||||||||||||||||MIC^Observation of type microbio<br/>logy^HL70411^^^^2.5.1||CC^Copies Requested^HL70507|625-4^Bacteria identified in Stool by Culture^LN^3456543^CULTURE STOO<br/>L^99USL^2.52^^Stool Culture<br/>
         </p>
         <p>OBX|1|SN|28-1^Ampicillin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN^^^^2.52|^1^1^Islt-2|&lt;^0.06|ug/mL<br/>^^UCUM^^^^1.9||S|||F|||201509231400|||||201509261100||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test Park^^Los An<br/>geles^CA^90067^^B|5432178916^Knowsalot^Phil^J.^^^^^NPI^L^^^NPI||||RSLT|SUR<br/>
         </p>
         <p>OBX|2|SN|267-5^Gentamicin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN^^^^2.52|^1^1^Islt-2|^0.05|ug/mL<br/>^^UCUM^^^^1.9||S|||F|||201509231400|||||201509261100||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test Park^^Los An<br/>geles^CA^90067^^B|5432178916^Knowsalot^Phil^J.^^^^^NPI^L^^^NPI||||RSLT|SUR<br/>
         </p>
         <p>OBX|3|SN|185-9^Ciprofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN^^^^2.52|^1^1^Islt-2|^0.05|ug<br/>/mL^^UCUM^^^^1.9||S|||F|||201509231400|||||201509261100||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test Park^^Los<br/> Angeles^CA^90067^^B|5432178916^Knowsalot^Phil^J.^^^^^NPI^L^^^NPI||||RSLT|SUR<br/>
         </p>
         <p>ORC|RE||R-783274-4^NIST Lab Filler|GORD874255^NIST EHR||||||||5742200012^Radon^Nicholas^^^^^^NPI^L^^^NPI|||||||||||||||<br/>||||625-4^Bacteria identified in Stool by Culture^LN^3456543^CULTURE STOOL^99USL^2.52^^Stool Culture<br/>
         </p>
         <p>OBR|3||R-783274-4^NIST Lab Filler|50545-3^Bacterial susceptibility panel in Isolate by Minimum inhibitory concentration<br/> (MIC)^LN^^^^2.52^^Bacteria susceptibility|||201509231400||||G|||||5742200012^Radon^Nicholas^^^^^^NPI^L^^^NPI||||||20150<br/>927112054|||F|625-4&amp;Bacteria identified in Stool by Culture&amp;LN&amp;&amp;&amp;&amp;2.52&amp;&amp;Stool Culture^&amp;3&amp;1&amp;Islt-3||10092000194^Hamlin^Pa<br/>fford^^^^^^NPI^L^^^NPI|ORD723222-4&amp;NIST EHR^R-783274-4&amp;NIST Lab Filler||||||||||||||||||MIC^Observation of type microbio<br/>logy^HL70411^^^^2.5.1||CC^Copies Requested^HL70507|625-4^Bacteria identified in Stool by Culture^LN^3456543^CULTURE STOO<br/>L^99USL^2.52^^Stool Culture<br/>
         </p>
         <p>OBX|1|SN|28-1^Ampicillin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN^^^^2.52|^1^1^Islt-3|&lt;^16|ug/mL^^<br/>UCUM^^^^1.9||I|||F|||201509231400|||||201509261100||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test Park^^Los Ange<br/>les^CA^90067^^B|5432178916^Knowsalot^Phil^J.^^^^^NPI^L^^^NPI||||RSLT|SUR<br/>
         </p>
      </div>
   </body>
</html>